Soleno Therapeutics, Inc. announced that it will receive $59,988,250 in funding on October 2, 2023. The company will issue convertible preferred shares and option, warrant or other right to acquire another security in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.82 USD | +0.35% | +0.42% | +12.25% |
May. 13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
May. 10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.25% | 1.66B | |
+8.64% | 114B | |
+10.33% | 104B | |
-12.69% | 22.41B | |
-0.41% | 22.28B | |
-5.80% | 19.07B | |
-37.36% | 18B | |
-5.36% | 17.89B | |
+6.83% | 14.28B | |
+36.31% | 12.55B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics, Inc. announced that it expects to receive $59.98825 million in funding